In Melbourne, Australia, it is currently 43 °C (109 °F), and to someone with neuromyelitis optica spectrum disorder (NMOSD), that kind of temperature is scary. Heat makes my pain and fatigue ...
Abstract: Vision-language pre-training models have demonstrated outstanding performance on a wide range of multimodal tasks. Nevertheless, they remain susceptible to multimodal adversarial examples.
I was, given my interest in virtual and augmented reality, already primed to have a high degree of interest in the Vision Pro, but even so, I appreciate how you have gone out of your way to make sure ...
Optic neuritis, a common multiple sclerosis symptom, causes vision loss due to optic nerve inflammation. This experimental therapy aims to protect vision and nerve structure; a global Phase 3 trial is ...
Please provide your email address to receive an email when new articles are posted on . If approved, privosegtor would become the first neuroprotective therapy for optic neuropathies. The PIONEER 1 ...
Oculis Holding (OCS) added ~11% on Tuesday after the Swiss drug developer announced the breakthrough therapy designation for its eye disease therapy Privosegtor as a treatment for optic neuritis (ON), ...
Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
Privosegtor showed significant visual function improvement and anatomical preservation in the phase 2 ACUITY trial for optic neuritis. The PIONEER program includes 3 pivotal trials to support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results